Von Willebrand Factor, Factor VIII, and Other Acute Phase Reactants as Biomarkers of Inflammation and Endothelial Dysfunction in Chronic Graft-Versus-Host Disease

Abstract

Chronic graft-versus-host disease (cGvHD) is an immune mediated late complication of allogeneic hematopoietic stem cell transplantation (alloHSCT). Discovery of adequate biomarkers could identify high-risk patients and provide an effective pre-emptive intervention or early modification of therapeutic strategy, thus reducing prevalence and severity of the disease among long-term survivors of alloHSCT. Inflammation, endothelial injury, and endothelial dysfunction are involved in cGvHD development. Altered levels of acute phase reactants have shown a strong correlation with the activity of several immune mediated disorders and are routinely used in clinical practice. Since elevated von Willebrand factor (VWF) and factor VIII (FVIII) levels have been described as acute phase reactants that may indicate endothelial dysfunction and inflammation in different settings, including chronic autoimmune diseases, they could serve as potential candidate biomarkers of cGvHD. In this review we focused on reported data regarding VWF and FVIII as well as other markers of inflammation and endothelial dysfunction, evaluating their potential role in cGvHD.

Introduction

Chronic graft-versus-host disease (cGvHD) is an iatrogenic, immune mediated complication of allogeneic hematopoietic stem cell transplantation (alloHSCT) with clinical features resembling aspects of several autoimmune disorders. With its high incidence of approximately 50% (1) and mortality of approximately 25% (2), cGvHD is a major burden on quality of life and long-term survival following alloHSCT. Considering the fact that improvement of transplantation techniques allowed an increased number of patients to undergo alloHSCT and resulted in longer survival, the future incidence of cGvHD is expected to become even higher (1). Despite tremendous efforts of the scientific community put into research of cGvHD biology, a significant breakthrough in treatment strategies has not been achieved yet. One of the major obstacles for further progress is the absence of biomarkers suitable for clinical use. An ideal biomarker would be a specific agent that is active early in cGvHD development and that reliably identifies high-risk patients. This biomarker would allow developing of effective pre-emptive intervention, thus reducing incidence and severity of cGvHD. Furthermore, a specific marker that could provide earlier and more accurate initial assessment of disease intensity, or detect therapeutic response before improvement or worsening of clinical manifestations, could revolutionize the therapeutic approach. For all these reasons, along with the search for an effective treatment, the search for a biomarker that has satisfactory specificity and sensitivity has become one of the top priorities of researchers and clinicians (3, 4). However, the elusive etiology of cGvHD significantly hinders this search so far, especially when masked by multifarious impacts that can modulate course of illness. It is widely known that both inflammation and endothelial injury persist long after alloHSCT, and are involved in cGvHD development (5–8). Von Willebrand factor (VWF) and factor VIII (FVIII) are coagulation factors, as well as acute phase reactants indicating endothelial dysfunction and inflammation in different settings. Therefore, they could serve as potentially interesting candidate biomarkers of cGvHD. In this review we focused on reported data regarding VWF and FVIII, and other markers of inflammation and endothelial dysfunction, evaluating their potential role in cGvHD.

Von Willebrand Factor and Factor VIII

General Considerations

Von Willebrand factor and FVIII are widely known as coagulation factors that play an important role in hemostasis. Beside the critical role of VWF in “platelet plug” formation (bridging molecule for platelet adhesion and promoting platelet aggregation) at sites of vascular injury, it also serves as a carrier of FVIII, protecting it from proteolytic degradation and transporting it to sites of injury, thus enhancing fibrin formation (9). A detailed overview of VWF and FVIII physiology is shown in Table 1. In this review we will focus on the fact that both VWF and FVIII are considered positive acute phase reactants in settings of inflammation and endothelial activation (11).

Although synthesis regulation of VWF and FVIII is yet to be completely elucidated, it seems that different endothelial cells produce each of them, with an additional production of VWF by megakaryocytes. While most of VWF is synthesized in endothelium of larger extrahepatic vessels, FVIII is synthesized mostly in hepatic sinusoidal endothelial cells. Interestingly, murine models have shown predominant distribution of VWF mRNA in lung and brain, indicating that VWF is differently expressed in different tissues (12). It should be emphasized that VWF and FVIII are the only coagulation factors that are not being produced by liver hepatocytes. Upon synthesis VWF is stored in specialized organelles; in smaller quantities as α granules of platelets, but mostly as Weibel-Palade bodies in vascular endothelial cells. Since endothelium represents the first line of defense from noxious stimuli, its activation caused by vascular injury of any etiology, results in secretion of VWF from Weibel-Palade bodies into the plasma. Secretion can be provoked by different inflammatory mediators released from resident immune cells, mostly tissue macrophages (13), and it results not only in direct adhesive interaction of VWF with leukocytes and trans-endothelial migration (14), but also in stimulation of other proinflammatory pathways such as complement and neutrophil extracellular traps (15). Moreover, proinflammatory agents, such as P-selectin are also released from Weibel-Palade bodies (16) further supporting the inflammatory response.

While VWF is well-recognized as the carrier of FVIII in plasma and protector of its degradation, the possible impact of FVIII on VWF plasma levels is poorly resolved. Some studies described a synergistic role of FVIII and platelets on the cleavage of VWF multimers by a disintegrin and metalloproteinase with ADAMTS13 (a thrombospondin type 1 motif, member 13) (17), while study with FVIII deficient mouse model revealed increased VWF content in the liver endothelium and increased VWF plasma levels, which was associated with hepatic low-grade inflammation (18).

Clinical Biomarker Utility

The clinical utility of VWF and FVIII as biomarkers has been questioned due to a possible influence by many extrinsic patient related parameters, such as age, body weight, ABO antigen status, diet, smoking, ethnicity, and even exercise (10, 19–21). However, possible benefits of such a relatively cost-effective and non-invasive diagnostic tool encouraged extensive research in the field of cardiovascular diseases, resulting in clear distinction of patients at risk for major adverse cardiovascular events (22–24). Significant elevation of both biomarkers has been described in different states of acute stress, and lately a lot of attention has been given to the investigation of their role in connection between inflammation and procoagulant state caused by coronavirus 2019 (SARS-CoV-2) infection (25, 26). Elevation of VWF and FVIII was also reported in many long-lasting clinical conditions, including chronic autoimmune rheumatic diseases, pregnancy, malignancy, hyperthyroidism, hyperglycemia, hypertriglyceridemia, liver and renal disease (19, 27, 28). All these findings directed current research of VWF and FVIII toward elucidation of association between hemostasis, thrombosis, endothelial injury, and inflammation in a process jointly named as “thromboinflammation”. Although increase of these coagulation factors has been described in many vasculopathies and other states of hypoxia, this review mainly focusses on autoimmune diseases that clinically resemble cGvHD. Available knowledge of biomarker utility in different settings regarding VWF is summarized in Table 2, while one regarding FVIII is shown in Table 3. It is interesting to note that both VWF and FVIII level increase correlates with activity of autoimmune connective tissue diseases. In systemic sclerosis and systemic lupus erythematosus it has shown to be predictive of pulmonary involvement (31), which can be connected to localized endothelial synthesis of these factors. Pathogenesis of both of these diseases includes inflammation and microvascular changes that lead to hypoxia and, consequently, fibrosis which is similar as in cGvHD. From these studies it can be concluded that inflammation caused by autoimmune disease is a consequence of endothelial injury. However, a detailed analysis of the biomarker potential regarding VWF and FVIII, including their sensitivity and specificity, has not been performed yet.

VWF and FVIII in a Post-alloHSCT Setting

Despite the fact that increase of VWF and FVIII can also be caused by hematologic malignancies (100, 101), chemotherapy or autologous HSCT, their levels following alloHSCT are significantly more prominent (102, 103). It is considered that such increase in a post-alloHSCT setting reflects endothelial injury in addition to acute phase reaction. Endothelium is the first-line barrier against various transplant related toxic effects including cytostatic therapy, radiation, immunosuppression, and alloreactivity. Increase of VWF has already shown prognostic value for acute GvHD (aGvHD) development (104). Moreover, it has been reported that elevated levels of VWF and FVIII among patients diagnosed with aGvHD strongly correlate with endothelial activation but their role in aGvHD biology has not yet been defined (102, 105–108). Such findings suggest that the endothelium has a pathophysiological role in aGvHD development which goes beyond cytokine-mediated cell-to-cell communication. Interestingly, an increase of VWF level was proposed as a diagnostic marker of cGvHD among alloHSCT long-term survivors also (108), with its potential utility as sensitive biomarker of cGvHD activity (109). These reports, though, had a limited number of subjects and lacking methodology. However, recent preliminary results of a prospective study on a well-defined cohort of alloHSCT patients conducted by Pulanic at al. showed significantly higher levels of VWF and FVIII in the cGvHD group in comparison to patients who did not develop cGvHD (110). Further analysis revealed a close association between cGvHD activity and elevated levels of VWF, suggesting a potential causal relationship. It should also be noticed that thromboembolic events, including venous thromboembolism, have been associated with presence of both acute and chronic GvHD even 50 months after alloHSCT (111). Such observations could suggest a potential role of inflammation induced increase of coagulation factors FVIII and VWF in the pathogenesis of these events. Additionally, elevated levels of VWF were described as predictive of poor outcome for some vascular endothelial syndromes such as transplant-associated thrombotic microangiopathy (112, 113), and FVIII seems to be involved in the pathophysiology of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) after alloHSCT (114). The prognostic role of FVIII and VWF plasma levels in SOS/VOD has been investigated, but the results were too ambiguous for clinical use (115).

Chronic Graft-Versus-Host Disease and Markers of Inflammation and Endothelial Dysfunction

The term acute-phase reactants (APRs) relates to all markers whose measured plasma concentrations increase or decrease by at least 25% during inflammation or tissue injury (116). Most of APRs are proteins produced by the liver. Their production is regulated by cytokines like interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α) and interferon gamma (IFNγ) which are being produced by immune cells during the inflammation process. As already mentioned earlier, inflammation and endothelial injury are closely connected. Also, both processes have been described in the cGvHD setting, although less extensively studied than in aGVHD. The most comprehensive study addressing inflammation in cGvHD was performed by Grkovic and NCI group who investigated clinical laboratory markers of inflammation as determinants of cGvHD activity and severity (6). The authors proposed that reactive thrombocytosis, mediated by interleukin-6 (IL-6), might contribute to the pathogenesis of transforming growth factor beta (TGF-β) and platelet-derived growth factor (PDGF)-induced fibrosis and vascular thickening. Namely, though thrombocytopenia measured at time of diagnosis of cGvHD is among the strongest predictors of poor survival across many studies (117), this study has shown an association of increased platelets with cGvHD activity and with more severe skin and joint/fascia cGvHD involvement over a longer follow-up period after cGvHD presentation (6). This is in line with other studies identifying platelets as key regulators of the inflammatory response (118). In addition to that, strong association of low platelet counts at time of diagnosis of cGvHD and poor survival could be partly due to development of microangiopathic hemolytic anemia (defined by appearance of schistocytes in peripheral blood smears and thrombocytopenia) in some cases, and impaired splenic function may cause thrombocytopenia in others (117).

Endothelial injury caused by inflammation, on the other hand, has not been extensively studied in cGvHD so far. However, an increase of vascular inflammation markers, such as endothelin-1, gelsolin, and anti-LG3 (autoantibodies against perlecan/LG3), was observed, confirming thus important role of endothelial injury and inflammation in the onset of cGvHD (119). Of note, endothelial injury is usually characterized by induction of proinflammatory cytokines (TNF-α, IL-6, IL-10, IL-1β, etc.) and by decreased levels of anti-inflammatory cytokines (TGF-β, IL-15), increased release of coagulation factors (VWF and FVIII), and overexpression of soluble and membrane-bound adhesion molecules (ICAM-1 (intercellular adhesion molecule 1), VCAM-1 (vascular cell adhesion protein 1), E-selectin) (120, 121). Interestingly, in contrast to multitude reports in aGvHD, there is no cGvHD data available even on basic hemostatic APRs, such as fibrinogen, D-dimer, thrombomodulin, and plasminogen activator inhibitor (PAI-1), a well-known marker of endothelial damage in SOS/VOD. Moreover, although inadequate activation of natural anticoagulants has been reported among patients following HSCT (107), no studies with longer follow-ups, describing changes among cGvHD patients in particular, were found. Aside from hemostatic APRs, great progress in omnics technique resulted in a number of novel potential cGvHD biomarkers, further reflecting the complex biology of cGvHD. For example, an interesting study with a panel of four markers (C-X-C motif chemokine ligand 9 (CXCL9), suppression of tumorigenicity 2 (ST2), osteopontin (OPN) and matrix metalloproteinase-3 (MMP3) measured 100 days after alloHSCT showed predictability for cGvHD development (122). The most important APRs and markers of endothelial dysfunction that have been investigated as potential cGvHD biomarkers are summarized in Table 4. However, it has to be stated that there is lack of standardized methods to separate inflammation in general from endothelial injury.

Discussion

Elucidation of immunological processes in the recovery period following alloHSCT remains challenging, especially in context of aGvHD and cGvHD. It is well established that endothelial activation and injury enhance the occurrence of aGvHD (134). Furthermore, an increasing number of scientists advocate the existence of an endothelial form of GvHD (135). Pioneers of this thinking, Tichelli and Gratwohl, supported the hypothesis of the vascular endothelium as a target of GvHD-mediated immune responses, which were previously described by Biedermann and colleagues (108). In addition, there is also in vitro evidence that some of the endothelium targeting immunological effector cells are in fact endothelial-, not just allo-specific (136, 137). Moreover, Tichelli and Gratwohl proposed that vascular endothelial syndromes should be considered as different forms of aGvHD which are reflected by organ-related injury. Another support to this opinion was given by connecting endothelial damage to steroid-refractory aGvHD (138). More recently publications demonstrate a reduction of aGvHD severity by experimentally using the endothelium-protecting agents sildenafil and defibrotide (139–141). Of note, defibrotide can also reduce the allogenicity of endothelial cells towards CD8+ T cells (142).

As for cGvHD, although it is characterized by impaired immune tolerance mechanisms affecting innate and adaptive immunity, elevated levels of inflammation and endothelial injury are also present, albeit less well elaborated so far (6, 108). Although the role of endothelial injury in cGvHD biology is not fully elucidated yet, it is clear that disease activity correlates with activation of the endothelium. Such activation cannot be attributed to acute conditioning toxicity or engraftment, considering the long period of time passing between these events and cGvHD diagnosis. Taking into consideration the proportional increase of VWF in relation to cGvHD activity and severity, the most probable reason for endothelial activation must be immune-related mechanisms. It was proposed earlier that endothelial cells of small vessels can act as antigen presenting cells (APC), even in the absence of professional APC (143). Activated endothelial cells (EC) show increased surface histocompatibility antigens and co-stimulatory molecules, rendering them more susceptible to a direct immune attack by alloreactive donor T cells. The resulting EC activation and injury can facilitate the passage of donor-derived cellular and soluble effectors from the blood and into recipient tissues (5). Biedermann et al. described infiltration of alloreactive cytotoxic T lymphocytes in the upper dermis of cGvHD patient with sclerotic form of skin involvement and subsequent rarefaction of small vessels, which argues in favor of this observation (108). Moreover, it has been suggested that neovascularization inhibition supported by activated donor T cells may contribute to a graft-versus-leukemia (GvL) effect, which can explain the protective role of active GvHD in prevention of tumor relapse (144). Another investigation showed partial reconstitution of microvessels among long-term survivors after alloHSCT (median follow-up was 17 years in this study), with complete recovery of microvascular remodeling after resolution of skin cGvHD (145). In an interesting study performed by Willemze et al. percentage of EC chimerism was higher when measured over a longer period of time after alloHSCT (146). It can be concluded that microvascular loss and resultant tissue ischemia may contribute to target organ fibrosis characteristic of cGvHD and that the effect may be reversible if treated on time, pointing to a possible role for donor derived EC in repair of damaged blood vessels. Tichelli and Gratwohl additionally suggested a causative link between inflammation, endothelial injury and the increased risk of cardiovascular diseases reported among long-term alloHSCT survivors. They actually used a simple and logical explanation, connecting an accelerated atherosclerosis to endothelial injury which is caused by persistent vascular inflammation and provoked by immunological mechanisms of cGvHD (135). Considering all the facts, endothelium-protecting agents could significantly diminish this vicious circle of chronic inflammation, endothelial damage, and ischemia, and for their possible beneficial effect, low side-effect profile and preservation of GVL effect, their usage should definitely be taken into consideration for future treatment strategies in cGvHD. However, there are some limitations of this concept: there is lack of markers that differentiate between endothelial damage and acute phase reaction well, as well as lack of drugs that are endothelial protective and that are tested in sufficiently large studies to prove that endothelial protection is a goal that can be achieved.

To conclude, in search for much needed biomarkers of cGvHD for clinical use, this review draws attention to acute phase reactants that may be associated with cGvHD activity and severity of cGvHD organ involvement. As non-invasive, readily available, and cost-efficient markers of endothelial activation, VWF and FVIII could provide valuable insight into cGvHD activity. Their elevation has a promising biomarker potential for an early diagnosis and as surrogate for activity of the disease. This concept is further underpinned by their proven good prognostic value in chronic autoimmune diseases clinically resembling cGvHD. In addition to the aforementioned factors it may also be helpful to assess endothelium-derived microvesicles for endothelial injury and procoagulant activity (147). Still, the influence of patient-related parameters should definitely be taken into consideration, and for that reason further prospective studies addressing this issue and the precise role of endothelial injury in cGvHD in general are needed.

Funding

This work was supported by European Cooperation in Science & Technology under the COST Action CA17138 (Integrated European Network on Chronic Graft Versus Host Disease) and by the Croatian Science Foundation Project IP-2016-06-8046 entitled “New biomarkers for chronic Graft-versus-Host disease”.

Disclaimer

The opinions expressed here are those of the authors and do not represent the official position of the National Institutes of Health or the US Government.

References

• 1

  Arai S Arora M Wang T Spellman SR He W Couriel DR et al . Increasing Incidence of Chronic Graft-Versus-Host Disease in Allogeneic Transplantation: A Report From the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant (2015) 21(2):266–74. doi: 10.1016/j.bbmt.2014.10.021

  • CrossRef
  • Google Scholar

• 2

  Grube M Holler E Weber D Holler B Herr W Wolff D . Risk Factors and Outcome of Chronic Graft-Versus-Host Disease After Allogeneic Stem Cell Transplantation—Results From a Single-Center Observational Study. Biol Blood Marrow Transplant (2016) 22(10):1781–91. doi: 10.1016/j.bbmt.2016.06.020

  • CrossRef
  • Google Scholar

• 3

  Wolff D Greinix H Lee SJ Gooley T Paczesny S Pavletic S et al . Biomarkers in Chronic Graft-Versus-Host Disease: Quo Vadis? Bone Marrow Transplant (2018) Jul 153(7):832–7. doi: 10.1038/s41409-018-0092-x

  • CrossRef
  • Google Scholar

• 4

  Paczesny S Hakim FT Pidala J Cooke KR Lathrop J Griffith LM et al . National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: III. The 2014 Biomarker Working Group Report. Biol Blood Marrow Transplant (2015) 21(5):780–92. doi: 10.1016/j.bbmt.2015.01.003

  • CrossRef
  • Google Scholar

• 5

  Cooke KR Luznik L Sarantopoulos S Hakim FT Jagasia M Fowler DH et al . The Biology of Chronic Graft-versus-Host Disease: A Task Force Report From the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease. Biol Blood Marrow Transplant (2017) 23(2):211–34. doi: 10.1016/j.bbmt.2016.09.023

  • CrossRef
  • Google Scholar

• 6

  Grkovic L Baird K Steinberg SM Williams KM Pulanic D Cowen EW et al . Clinical Laboratory Markers of Inflammation as Determinants of Chronic Graft-Versus-Host Disease Activity and NIH Global Severity. Leukemia (2012) 26(4):633–43. doi: 10.1038/leu.2011.254

  • CrossRef
  • Google Scholar

• 7

  Penack O Luft T . Editorial: Endothelial Dysfunction During Inflammation and Alloimmunity. Front Immunol (2018) 9:2886. doi: 10.3389/fimmu.2018.02886

  • CrossRef
  • Google Scholar

• 8

  Medinger M Tichelli A Bucher C Halter J Dirnhofer S Rovo A et al . GVHD After Allogeneic Haematopoietic SCT for AML: Angiogenesis, Vascular Endothelial Growth Factor and VEGF Receptor Expression in the BM. Bone Marrow Transplant (2013) 48(5):715–21. doi: 10.1038/bmt.2012.200

  • CrossRef
  • Google Scholar

• 9

  Pipe SW Montgomery RR Pratt KP Lenting PJ Lillicrap D . Life in the Shadow of a Dominant Partner: The FVIII-VWF Association and its Clinical Implications for Hemophilia a. Blood Am Soc Hematol (2016) 128:2007–16. doi: 10.1182/blood-2016-04-713289

  • CrossRef
  • Google Scholar

• 10

  Terraube V O’Donnell JS Jenkins PV . Factor VIII and Von Willebrand Factor Interaction: Biological, Clinical and Therapeutic Importance. Haemophilia (2010) 16:3–13. doi: 10.1111/j.1365-2516.2009.02005.x

  • CrossRef
  • Google Scholar

• 11

  Kawecki C Lenting PJ Denis CV . Von Willebrand Factor and Inflammation. J Thromb Haemost (2017) 15(7):1285–94. doi: 10.1111/jth.13696

  • CrossRef
  • Google Scholar

• 12

  Yamamoto K de Waard V Fearns C Loskutoff DJ . Tissue Distribution and Regulation of Murine Von Willebrand Factor Gene Expression In Vivo. Blood (1998) 92(8):2791–801. doi: 10.1182/blood.V92.8.2791.420k24_2791_2801

  • CrossRef
  • Google Scholar

• 13

  Chen J Chung DW . Inflammation, Von Willebrand Factor, and ADAMTS13. Blood (2018) 132(2):141–7. doi: 10.1182/blood-2018-02-769000

  • CrossRef
  • Google Scholar

• 14

  Petri B Broermann A Li H Khandoga AG Zarbock A Krombach F et al . Von Willebrand Factor Promotes Leukocyte Extravasation. Blood (2010) 116(22):4712–9. doi: 10.1182/blood-2010-03-276311

  • CrossRef
  • Google Scholar

• 15

  Gragnano F Sperlongano S Golia E Natale F Bianchi R Crisci M et al . The Role of Von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy. Mediators Inflamm (2017) 2017:5620314. doi: 10.1155/2017/5620314

  • CrossRef
  • Google Scholar

• 16

  Pendu R Terraube V Christophe OD Gahmberg CG De Groot PG Lenting PJ et al . P-Selectin Glycoprotein Ligand 1 and β2-Integrins Cooperate in the Adhesion of Leukocytes to Von Willebrand Factor. Blood (2006) 108(12):3746–52. doi: 10.1182/blood-2006-03-010322

  • CrossRef
  • Google Scholar

• 17

  Skipwith CG Cao W Zheng XL . Factor VIII and Platelets Synergistically Accelerate Cleavage of Von Willebrand Factor by ADAMTS13 Under Fluid Shear Stress. J Biol Chem (2010) 285:28596–603. doi: 10.1074/jbc.M110.131227

  • CrossRef
  • Google Scholar

• 18

  Kiouptsi K Grill A Mann A Döhrmann M Lillich M Jäckel S et al . Mice Deficient in the Anti-Haemophilic Coagulation Factor VIII Show Increased Von Willebrand Factor Plasma Levels. PLoS One (2017) 12(8):e0183590. doi: 10.1371/journal.pone.0183590

  • CrossRef
  • Google Scholar

• 19

  Conlan MG Folsom AR Finch A Davis CE Sorlie P Marcucci G et al . Associations of Factor VIII and Von Willebrand Factor With Age, Race, Sex, and Risk Factors for Atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost (1993) 70(3):380–5. doi: 10.1055/s-0038-1649589

  • CrossRef
  • Google Scholar

• 20

  Ingerslev J . A Sensitive ELISA for Von Willebrand Factor (Vwf:Ag). Scand J Clin Lab Invest (1987) 47(2):143–9. doi: 10.3109/00365518709168882

  • CrossRef
  • Google Scholar

• 21

  Cohen RJ Epstein SE Cohen LS Dennis LH . Alterations of Fibrinolysis and Blood Coagulation Induced by Exercise, and the Role of Beta-Adrenergic-Receptor Stimulation. Lancet (1968) 2(7581):1264–6. doi: 10.1016/S0140-6736(68)91760-1

  • CrossRef
  • Google Scholar

• 22

  Alonso A Tang W Agarwal SK Soliman EZ Chamberlain AM Folsom AR . Hemostatic Markers are Associated With the Risk and Prognosis of Atrial Fibrillation: The ARIC Study. Int J Cardiol (2012) 155(2):217–22. doi: 10.1016/j.ijcard.2010.09.051

  • CrossRef
  • Google Scholar

• 23

  Sonneveld MAH Franco OH Ikram MA Hofman A Kavousi M De Maat MPM et al . Von Willebrand Factor, ADAMTS13, and the Risk of Mortality: The Rotterdam Study. Arterioscler Thromb Vasc Biol (2016) 36(12):2446–51. doi: 10.1161/ATVBAHA.116.308225

  • CrossRef
  • Google Scholar

• 24

  Folsom AR Rosamond WD Shahar E Cooper LS Aleksic N Nieto FJ et al . Prospective Study of Markers of Hemostatic Function With Risk of Ischemic Stroke. Circulation (1999) 100(7):736–42. doi: 10.1161/01.CIR.100.7.736

  • CrossRef
  • Google Scholar

• 25

  Ladikou EE Sivaloganathan H Milne KM Arter WE Ramasamy R Saad R et al . Von Willebrand Factor (vWF): Marker of Endothelial Damage and Thrombotic Risk in COVID-19? Clin Med (2020) 20(5):e178–82. doi: 10.7861/clinmed.2020-0346

  • CrossRef
  • Google Scholar

• 26

  Goshua G Pine AB Meizlish ML Chang CH Zhang H Bahel P et al . Endotheliopathy in COVID-19-associated Coagulopathy: Evidence From a Single-Centre, Cross-Sectional Study. Lancet Haematol (2020) 7(8):e575–82. doi: 10.1016/S2352-3026(20)30216-7

  • CrossRef
  • Google Scholar

• 27

  Habe K Wada H Matsumoto T Ohishi K Ikejiri M Tsuda K et al . Plasma ADAMTS13, Von Willebrand Factor (VWF), and VWF Propeptide Profiles in Patients With Connective Tissue Diseases and Antiphospholipid Syndrome. Clin Appl Thromb (2017) 23(6):622–30. doi: 10.1177/1076029615625832

  • CrossRef
  • Google Scholar

• 28

  Danesh J Wheeler JG Hirschfield GM Eda S Eiriksdottir G Rumley A et al . C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease. N Engl J Med (2004) 350(14):1387–97. doi: 10.1056/NEJMoa032804

  • CrossRef
  • Google Scholar

• 29

  Scheja A Åkesson A Geborek P Wildt M Wollheim CB Wollheim FA et al . Von Willebrand Factor Propeptide as a Marker of Disease Activity in Systemic Sclerosis (Scleroderma). Arthritis Res (2001) 3(3):178–82. doi: 10.1186/ar295

  • CrossRef
  • Google Scholar

• 30

  Herrick AL Illingworth K Blann A Hay CRM Hollis S Jayson MIV . Von Willebrand Factor, Thrombomodulin, Thromboxane, β-Thromboglobulin and Markers of Fibrinolysis in Primary Raynaud’s Phenomenon and Systemic Sclerosis. Ann Rheum Dis (1996) 55(2):122–7. doi: 10.1136/ard.55.2.122

  • CrossRef
  • Google Scholar

• 31

  Barnes T Gliddon A Doré CJ Maddison P Moots RJ . Baseline vWF Factor Predicts the Development of Elevated Pulmonary Artery Pressure in Systemic Sclerosis. Rheumatology (United Kingdom) (2012) 51(9):1606–9. doi: 10.1093/rheumatology/kes068

  • CrossRef
  • Google Scholar

• 32

  Nossent JC Raymond WD Eilertsen GØ . Increased Von Willebrand Factor Levels in Patients With Systemic Lupus Erythematosus Reflect Inflammation Rather Than Increased Propensity for Platelet Activation. Lupus Sci Med (2016) 3(1):e000162. doi: 10.1136/lupus-2016-000162

  • CrossRef
  • Google Scholar

• 33

  Gürol G Ciftci IH Harman H Karakece E Kamanli A Tekeoglu I . Roles of Claudin-5 and Von Willebrand Factor in Patients With Rheumatoid Arthritis. Int J Clin Exp Pathol (2015) 8(2):1979–84.

  • Google Scholar

• 34

  Lau CS McLaren M Hanslip J Kerr M Belch JJF . Abnormal Plasma Fibrinolysis in Patients With Rheumatoid Arthritis and Impaired Endothelial Fibrinolytic Response in Those Complicated by Vasculitis. Ann Rheum Dis (1993) 52(9):643–9. doi: 10.1136/ard.52.9.643

  • CrossRef
  • Google Scholar

• 35

  D’Cruz D Direskeneli H Khamashta M Hughes GRV . Lymphocyte Activation Markers and Von Willebrand Factor Antigen in Wegener’s Granulomatosis: Potential Markers for Disease Activity. J Rheumatol (1999) 26(1):103–9.

  • Google Scholar

• 36

  Alkaabi JK Gravell D Al-Haddabi H Pathare A . Haemostatic Parameters in Patients With Behçet’s Disease. Sultan Qaboos Univ Med J (2014) 14(2):e190–6.

  • Google Scholar

• 37

  Lau CS Mclaren M Belch JJF . Factor VIII Von Willebrand Factor Antigen Levels Correlate With Symptom Severity in Patients With Raynaud’s Phenomenon. Rheumatology (1991) 30(6):433–6. doi: 10.1093/rheumatology/30.6.433

  • CrossRef
  • Google Scholar

• 38

  Rose PE Kavi J Chant I Taylor CM Struthers GS Robertson M . Factor VIII Von Willebrand Protein in Haemolytic Uraemic Syndrome and Systemic Vasculitides. Lancet (1990) 335(8688):500–2. doi: 10.1016/0140-6736(90)90736-O

  • CrossRef
  • Google Scholar

• 39

  De Mattia D Penza R Giordano P Del Vecchio GC Aceto G Altomare M et al . Von Willebrand Factor and Factor XIII in Children With Henoch-Schonlein Purpura. Pediatr Nephrol (1995) 9(5):603–5. doi: 10.1007/BF00860949

  • CrossRef
  • Google Scholar

• 40

  Fan M Wang X Peng X Feng S Zhao J Liao L et al . Prognostic Value of Plasma Von Willebrand Factor Levels in Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis. BMC Cardiovasc Disord (2020) 20. doi: 10.1186/s12872-020-01375-7

  • CrossRef
  • Google Scholar

• 41

  Sonneveld MAH Cheng JM Oemrawsingh RM de Maat MPM Kardys I Garcia-Garcia HM et al . Von Willebrand Factor in Relation to Coronary Plaque Characteristics and Cardiovascular Outcome Results of the Atheroremo-Ivus Study. Thromb Haemost (2014) 113(3):577–84. doi: 10.1160/TH14-07-0589

  • CrossRef
  • Google Scholar

• 42

  Kato Y Iwata A Futami M Yamashita M Imaizumi S Kuwano T et al . Impact of Von Willebrand Factor on Coronary Plaque Burden in Coronary Artery Disease Patients Treated With Statins. Medicine (United States) (2018) 97(17):e0589. doi: 10.1097/MD.0000000000010589

  • CrossRef
  • Google Scholar

• 43

  Lip GYH Lydakis C Nuttall SL Landray MJ Watson RDS Blann AD . A Pilot Study of Streptokinase-Induced Endothelial Injury and Platelet Activation Following Acute Myocardial Infarction. J Intern Med (2000) 248(4):316–8. doi: 10.1046/j.1365-2796.2000.00738.x

  • CrossRef
  • Google Scholar

• 44

  Blann AD Waite MA . Von Willebrand Factor and Soluble E-selectin in Hypertension: Influence of Treatment and Value in Predicting the Progression of Atherosclerosis. Coron Artery Dis (1996) 7(2):143–7. doi: 10.1097/00019501-199602000-00008

  • CrossRef
  • Google Scholar

• 45

  Zhong C Xin M He L Sun G Shen F . Prognostic Value of Von Willebrand Factor in Patients With Atrial Fibrillation. Medicine (United States) (2018) 97:e11269. doi: 10.1097/MD.0000000000011269

  • CrossRef
  • Google Scholar

• 46

  Krishnamoorthy S Khoo CW Lim HS Lane DA Pignatelli P Basili S et al . Prognostic Role of Plasma Von Willebrand Factor and Soluble E-selectin Levels for Future Cardiovascular Events in a “Real-World” Community Cohort of Patients With Atrial Fibrillation. Eur J Clin Invest (2013) 43(10):1032–8. doi: 10.1111/eci.12140

  • CrossRef
  • Google Scholar

• 47

  Freynhofer MK Gruber SC Bruno V Höchtl T Farhan S Zaller V et al . Prognostic Value of Plasma Von Willebrand Factor and its Cleaving Protease ADAMTS13 in Patients With Atrial Fibrillation. Int J Cardiol (2013) 168(1):317–25. doi: 10.1016/j.ijcard.2012.09.056

  • CrossRef
  • Google Scholar

• 48

  Ye YZ Chang YF Wang BZ Ma YT Ma X . Prognostic Value of Von Willebrand Factor for Patients With Atrial Fibrillation: A Meta-Analysis of Prospective Cohort Studies. Postgrad Med J (2020) 96:267–76. doi: 10.1136/postgradmedj-2019-136842

  • CrossRef
  • Google Scholar

• 49

  Ancedy Y Berthelot E Lang S Ederhy S Boyer-Chatenet L Di Angelantonio E et al . Is Von Willebrand Factor Associated With Stroke and Death At Mid-Term in Patients With non-Valvular Atrial Fibrillation? Arch Cardiovasc Dis (2018) 111(5):357–69. doi: 10.1016/j.acvd.2017.08.004

  • CrossRef
  • Google Scholar

• 50

  Ohuchi H Hayama Y Miike H Suzuki D Nakajima K Iwasa T et al . Prognostic Value of Von Willebrand Factor in Adult Patients With Congenital Heart Disease. Heart (2020) 106(12):910–5. doi: 10.1136/heartjnl-2019-316007

  • CrossRef
  • Google Scholar

• 51

  Gombos T Makó V Cervenak L Papassotiriou J Kunde J Hársfalvi J et al . Levels of Von Willebrand Factor Antigen and Von Willebrand Factor Cleaving Protease (ADAMTS13) Activity Predict Clinical Events in Chronic Heart Failure. Thromb Haemost (2009) 102(3):573–80. doi: 10.1160/TH09-01-0036

  • CrossRef
  • Google Scholar

• 52

  Catto AJ Carter AM Barrett JH Bamford J Rice PJ Grant PJ . Von Willebrand Factor and Factor VIII:C in Acute Cerebrovascular Disease. Relationship to Stroke, Subtype and Mortality. Thromb Haemost (1997) 77(6):1104–8. doi: 10.1055/s-0038-1656120

  • CrossRef
  • Google Scholar

• 53

  Buchtele N Schwameis M Gilbert JC Schörgenhofer C Jilma B . Targeting Von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence. Thromb Haemost (2018) 118:959–78. doi: 10.1055/s-0038-1648251

  • CrossRef
  • Google Scholar

• 54

  Samai A Monlezun D Shaban A George A Dowell L Kruse-Jarres R et al . Von Willebrand Factor Drives the Association Between Elevated Factor VIII and Poor Outcomes in Patients With Ischemic Stroke. Stroke (2014) 45(9):2789–91. doi: 10.1161/STROKEAHA.114.006394

  • CrossRef
  • Google Scholar

• 55

  Tóth NK Székely EG Czuriga-Kovács KR Sarkady F Nagy O Lánczi LI et al . Elevated Factor VIII and Von Willebrand Factor Levels Predict Unfavorable Outcome in Stroke Patients Treated With Intravenous Thrombolysis. Front Neurol (2018) 8(JAN):721. doi: 10.3389/fneur.2017.00721

  • CrossRef
  • Google Scholar

• 56

  Frankel DS Meigs JB Massaro JM Wilson PWF O’Donnell CJ D’Agostino RB et al . Von Willebrand Factor, Type 2 Diabetes Mellitus, and Risk of Cardiovascular Disease: The Framingham Offspring Study. Circulation (2008) 118(24):2533–9. doi: 10.1161/CIRCULATIONAHA.108.792986

  • CrossRef
  • Google Scholar

• 57

  Peng X Wang X Fan M Zhao J Lin L Liu J . Plasma Levels of Von Willebrand Factor in Type 2 Diabetes Patients With and Without Cardiovascular Diseases: A Meta-Analysis. Diabetes Metab Res Rev (2020) 36:e3193. doi: 10.1002/dmrr.3193

  • CrossRef
  • Google Scholar

• 58

  Kovacevic KD Mayer FJ Jilma B Buchtele N Obermayer G Binder CJ et al . Von Willebrand Factor Antigen Levels Predict Major Adverse Cardiovascular Events in Patients With Carotid Stenosis of the ICARAS Study. Atherosclerosis (2019) 290:31–6. doi: 10.1016/j.atherosclerosis.2019.09.003

  • CrossRef
  • Google Scholar

• 59

  Ferlitsch M Reiberger T Hoke M Salzl P Schwengerer B Ulbrich G et al . Von Willebrand Factor as New Noninvasive Predictor of Portal Hypertension, Decompensation and Mortality in Patients With Liver Cirrhosis. Hepatology (2012) 56(4):1439–47. doi: 10.1002/hep.25806

  • CrossRef
  • Google Scholar

• 60

  Zou Z Yan X Li C Li X Ma X Zhang C et al . Von Willebrand Factor as a Biomarker of Clinically Significant Portal Hypertension and Severe Portal Hypertension: A Systematic Review and Meta-Analysis. BMJ Open (2019) 9:e025656. doi: 10.1136/bmjopen-2018-025656

  • CrossRef
  • Google Scholar

• 61

  Ding X-C Ma W-L Li M-K Liu S-W Liu X-Y Hai L et al . A Meta-Analysis of the Value of vWF in the Diagnosis of Liver Cirrhosis With Portal Hypertension. J Clin Transl Hepatol (2018) 6(4):1–6. doi: 10.14218/JCTH.2018.00036

  • CrossRef
  • Google Scholar

• 62

  Prasanna KS Goel A Amirtharaj GJ Ramachandran A Balasubramanian KA Mackie I et al . Plasma Von Willebrand Factor Levels Predict in-Hospital Survival in Patients With Acute-on-Chronic Liver Failure. Indian J Gastroenterol (2016) 35(6):432–40. doi: 10.1007/s12664-016-0708-2

  • CrossRef
  • Google Scholar

• 63

  Eidelberg A Kirubakaran R Nair SC Eapen CE Elias E Goel A . Systematic Review: Role of Elevated Plasma von-Willebrand Factor as Predictor of Mortality in Patients With Chronic Liver Disease. Eur J Gastroenterol Hepatol (2019) 31(10):1184–91. doi: 10.1097/MEG.0000000000001491

  • CrossRef
  • Google Scholar

• 64

  Horvatits T Drolz A Roedl K Herkner H Ferlitsch A Perkmann T et al . Von Willebrand Factor Antigen for Detection of Hepatopulmonary Syndrome in Patients With Cirrhosis. J Hepatol (2014) 61(3):544–9. doi: 10.1016/j.jhep.2014.04.025

  • CrossRef
  • Google Scholar

• 65

  Takaya H Kawaratani H Tsuji Y Nakanishi K Saikawa S Sato S et al . Von Willebrand Factor is a Useful Biomarker for Liver Fibrosis and Prediction of Hepatocellular Carcinoma Development in Patients With Hepatitis B and C. United European Gastroenterol J (2018) 6(9):1401–9. doi: 10.1177/2050640618779660

  • CrossRef
  • Google Scholar

• 66

  Maieron A Salzl P Peck-Radosavljevic M Trauner M Hametner S Schöfl R et al . Von Willebrand Factor as a New Marker for Non-Invasive Assessment of Liver Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C. Aliment Pharmacol Ther (2014) 39(3):331–8. doi: 10.1111/apt.12564

  • CrossRef
  • Google Scholar

• 67

  Aryal B Yamakuchi M Shimizu T Kadono J Furoi A Gejima K et al . Bivalent Property of Intra-Platelet VWF in Liver Regeneration and HCC Recurrence: A Prospective Multicenter Study. Cancer Biomark (2019) 26(1):51–61. doi: 10.3233/CBM-190168

  • CrossRef
  • Google Scholar

• 68

  Starlinger P Pereyra D Haegele S Braeuer P Oehlberger L Primavesi F et al . Perioperative Von Willebrand Factor Dynamics are Associated With Liver Regeneration and Predict Outcome After Liver Resection. Hepatology (2018) 67(4):1516–30. doi: 10.1002/hep.29651

  • CrossRef
  • Google Scholar

• 69

  Schwarz C Fitschek F Mittlböck M Saukel V Bota S Ferlitsch M et al . Von Willebrand Factor Antigen Predicts Outcomes in Patients After Liver Resection of Hepatocellular Carcinoma. Gut Liver (2020) 14(2):218–24. doi: 10.5009/gnl17115

  • CrossRef
  • Google Scholar

• 70

  Wannhoff A Rauber C Friedrich K Rupp C Stremmel W Weiss KH et al . Von Willebrand Factor and Alkaline Phosphatase Predict Re-Transplantation-Free Survival After the First Liver Transplantation. United European Gastroenterol J (2017) 5(1):86–93. doi: 10.1177/2050640616650060

  • CrossRef
  • Google Scholar

• 71

  Györi GP Pereyra D Rumpf B Hackl H Köditz C Ortmayr G et al . The Von Willebrand Factor Facilitates Model for End-Stage Liver Disease–Independent Risk Stratification on the Waiting List for Liver Transplantation. Hepatology (2020) 72(2):584–94. doi: 10.1002/hep.31047

  • CrossRef
  • Google Scholar

• 72

  Rhone P Zarychta E Bielawski K Ruszkowska-Ciastek B . Pre-Surgical Level of Von Willebrand Factor as an Evident Indicator of Breast Cancer Recurrence. Cancer Biomark (2020) 29(3):359–72. doi: 10.3233/CBM-191096

  • CrossRef
  • Google Scholar

• 73

  Obermeier HL Riedl J Ay C Koder S Quehenberger P Bartsch R et al . The Role of ADAMTS-13 and Von Willebrand Factor in Cancer Patients: Results From the Vienna Cancer and Thrombosis Study. Res Pract Thromb Haemost (2019) 3(3):503–14. doi: 10.1002/rth2.12197

  • CrossRef
  • Google Scholar

• 74

  Yao J Song A Cao W Chen S Zhou L Cao S et al . Clinical Significance of Anti-Endothelial Cell Antibody in Allogeneic Hematopoietic Stem Cell Transplantation Recipients With Graft-Versus-Host Disease. Int J Hematol (2014) 99(3):329–37. doi: 10.1007/s12185-014-1517-y

  • CrossRef
  • Google Scholar

• 75

  Guo R Yang J Liu X Wu J Chen Y . Increased Von Willebrand Factor Over Decreased ADAMTS-13 Activity is Associated With Poor Prognosis in Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Lab Anal (2018) 32(1):e22219. doi: 10.1002/jcla.22219

  • CrossRef
  • Google Scholar

• 76

  Hodak E Trattner A David M Kornbrot N Modan B Lurie H et al . Quantitative and Qualitative Assessment of Plasma Von Willebrand Factor in Classic Kaposi’s Sarcoma. J Am Acad Dermatol (1993) 28(2):217–21. doi: 10.1016/0190-9622(93)70030-W

  • CrossRef
  • Google Scholar

• 77

  Kastritis E Papassotiriou I Terpos E Roussou M Gavriatopoulou M Komitopoulou A et al . Clinical and Prognostic Significance of Serum Levels of Von Willebrand Factor and ADAMTS-13 Antigens in AL Amyloidosis. Blood (2016) 128(3):405–9. doi: 10.1182/blood-2016-02-702696

  • CrossRef
  • Google Scholar

• 78

  Lopes AAB Maeda NY . Circulating Von Willebrand Factor Antigen as a Predictor of Short-Term Prognosis in Pulmonary Hypertension. Chest (1998) 114(5):1276–82. doi: 10.1378/chest.114.5.1276

  • CrossRef
  • Google Scholar

• 79

  Ware LB Eisner MD Thompson BT Parsons PE Matthay MA . Significance of Von Willebrand Factor in Septic and Nonseptic Patients With Acute Lung Injury. Am J Respir Crit Care Med (2004) 170(7):766–72. doi: 10.1164/rccm.200310-1434OC

  • CrossRef
  • Google Scholar

• 80

  El Basset Abo El Ezz AA Abd El Hafez MA El Amrousy DM El Momen Suliman GA . The Predictive Value of Von Willebrand Factor Antigen Plasma Levels in Children With Acute Lung Injury. Pediatr Pulmonol (2017) 52(1):91–7. doi: 10.1002/ppul.23518

  • CrossRef
  • Google Scholar

• 81

  Van Der Zee P Rietdijk W Somhorst P Endeman H Gommers D . A Systematic Review of Biomarkers Multivariately Associated With Acute Respiratory Distress Syndrome Development and Mortality. Crit Care (2020) 24:243. doi: 10.1186/s13054-020-02913-7

  • CrossRef
  • Google Scholar

• 82

  Johansson MW Kruger SJ Schiebler ML Evans MD Sorkness RL Denlinger LC et al . Markers of Vascular Perturbation Correlate With Airway Structural Change in Asthma. Am J Respir Crit Care Med (2013) 188(2):167–78. doi: 10.1164/rccm.201301-0185OC

  • CrossRef
  • Google Scholar

• 83

  Rønnow SR Langholm LL Karsdal MA Manon-Jensen T Tal-Singer R Miller BE et al . Endotrophin, an Extracellular Hormone, in Combination With Neoepitope Markers of Von Willebrand Factor Improves Prediction of Mortality in the ECLIPSE COPD Cohort. Respir Res (2020) 21(1):202. doi: 10.1186/s12931-020-01461-6

  • CrossRef
  • Google Scholar

• 84

  Langholm LL Rønnow SR Sand JMB Leeming DJ Tal-Singer R Miller BE et al . Increased Von Willebrand Factor Processing in COPD, Reflecting Lung Epithelium Damage, is Associated With Emphysema, Exacerbations and Elevated Mortality Risk. Int J COPD (2020) 15:543–52. doi: 10.2147/COPD.S235673

  • CrossRef
  • Google Scholar

• 85

  Kayal S Jaïs JP Aguini N Chaudière J Labrousse J . Elevated Circulating E-selectin, Intercellular Adhesion Molecule 1, and Von Willebrand Factor in Patients With Severe Infection. Am J Respir Crit Care Med (1998) 157(3 PART I):776–84. doi: 10.1164/ajrccm.157.3.9705034

  • CrossRef
  • Google Scholar

• 86

  Rubin DB Wiener-Kronish JP Murray JF Green DR Turner J Luce JM et al . Elevated Von Willebrand Factor Antigen is an Early Plasma Predictor of Acute Lung Injury in Nonpulmonary Sepsis Syndrome. J Clin Invest (1990) 86(2):474–80. doi: 10.1172/JCI114733

  • CrossRef
  • Google Scholar

• 87

  Hyseni A Kemperman H De Lange DW Kesecioglu J De Groot PG Roest M . Active Von Willebrand Factor Predicts 28-Day Mortality in Patients With Systemic Inflammatory Response Syndrome. Blood (2014) 123(14):2153–6. doi: 10.1182/blood-2013-08-508093

  • CrossRef
  • Google Scholar

• 88

  Hovinga JAK Zeerleder S Kessler P Romani De Wit T Van Mourik JA Hack CE et al . ADAMTS-13, Von Willebrand Factor and Related Parameters in Severe Sepsis and Septic Shock. J Thromb Haemost (2007) 5(11):2284–90. doi: 10.1111/j.1538-7836.2007.02743.x

  • CrossRef
  • Google Scholar

• 89

  McElroy AK Erickson BR Flietstra TD Rollin PE Towner JS Nichol ST et al . Von Willebrand Factor is Elevated in Individuals Infected With Sudan Virus and is Associated With Adverse Clinical Outcomes. Viral Immunol (2015) 28(1):71–3. doi: 10.1089/vim.2014.0072

  • CrossRef
  • Google Scholar

• 90

  Alpoim PN Gomes KB Godoi LC Rios DR Carvalho MG Fernandes AP et al . ADAMTS13, FVIII, Von Willebrand Factor, ABO Blood Group Assessment in Preeclampsia. Clin Chim Acta (2011) 412(23–24):2162–6. doi: 10.1016/j.cca.2011.07.030

  • CrossRef
  • Google Scholar

• 91

  James JP Stevens TRJ Hall ND Maddison PJ Goulding NJ Silman A et al . Factor VIII Related Antigen in Connective Tissue Disease Patients and Relatives. Rheumatology (1990) 29(1):6–9. doi: 10.1093/rheumatology/29.1.6

  • CrossRef
  • Google Scholar

• 92

  Van Son WJ Brijker F Elema JD Tegzess AM Van Der Meer J . Elevated Factor VIII as a Marker for Vascular Type of Rejection After Renal Transplantation. Transplant Proc (1997) 29(1–2):161–3. doi: 10.1016/S0041-1345(96)00049-8

  • CrossRef
  • Google Scholar

• 93

  Jenkins PV Rawley O Smith OP O’Donnell JS . Elevated Factor VIII Levels and Risk of Venous Thrombosis. Br J Haematol (2012) 157(6):653–63. doi: 10.1111/j.1365-2141.2012.09134.x

  • CrossRef
  • Google Scholar

• 94

  Cosmi B Legnani C Cini M Favaretto E Palareti G . D-dimer and Factor VIII are Independent Risk Factors for Recurrence After Anticoagulation Withdrawal for a First Idiopathic Deep Vein Thrombosis. Thromb Res (2008) 122(5):610–7. doi: 10.1016/j.thromres.2007.12.024

  • CrossRef
  • Google Scholar

• 95

  Mattila N Seppänen H Mustonen H Przybyla B Haglund C Lassila R . Preoperative Biomarker Panel, Including Fibrinogen and FVIII, Improves Diagnostic Accuracy for Pancreatic Ductal Adenocarcinoma. Clin Appl Thromb (2018) 24(8):1267–75. doi: 10.1177/1076029618779133

  • CrossRef
  • Google Scholar

• 96

  Vormittag R Simanek R Ay C Dunkler D Quehenberger P Marosi C et al . High Factor VIII Levels Independently Predict Venous Thromboembolism in Cancer Patients: The Cancer and Thrombosis Study. Arterioscler Thromb Vasc Biol (2009) 29(12):2176–81. doi: 10.1161/ATVBAHA.109.190827

  • CrossRef
  • Google Scholar

• 97

  Castellón Rubio VE Segura PP Muñoz A Farré AL Ruiz LC Lorente JA . High Plasma Levels of Soluble P-Selectin and Factor VIII Predict Venous Thromboembolism in Non-Small Cell Lung Cancer Patients: The Thrombo-Nsclc Risk Score. Thromb Res (2020) 196:349–54. doi: 10.1016/j.thromres.2020.09.021

  • CrossRef
  • Google Scholar

• 98

  Dossenbach-Glaninger A van Trotsenburg M Krugluger W Dossenbach MR Oberkanins C Huber J et al . Elevated Coagulation Factor VIII and the Risk for Recurrent Early Pregnancy Loss. Thromb Haemost (2004) 91(4):694–9. doi: 10.1160/TH03-09-0554

  • CrossRef
  • Google Scholar

• 99

  Sakamoto S Kawabata H Kanda J Uchiyama T Mizumoto C Kondo T et al . Differing Impacts of Pretransplant Serum Ferritin and C-Reactive Protein Levels on the Incidence of Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation. Int J Hematol (2013) 97(1):109–16. doi: 10.1007/s12185-012-1229-0

  • CrossRef
  • Google Scholar

• 100

  Minnema MC Fijnheer R De Groot PG Lokhorst HM . Extremely High Levels of Von Willebrand Factor Antigen and of Procoagulant Factor VIII Found in Multiple Myeloma Patients are Associated With Activity Status But Not With Thalidomide Treatment. J Thromb Haemost (2003) 1(3):445–9. doi: 10.1046/j.1538-7836.2003.00083.x

  • CrossRef
  • Google Scholar

• 101

  Mohren M Jentsch-Ullrich K Koenigsmann M Kropf S Schalk E Lutze G . High Coagulation Factor VIII and Von Willebrand Factor in Patients With Lymphoma and Leukemia. Int J Hematol (2016) 103(2):189–95. doi: 10.1007/s12185-015-1913-y

  • CrossRef
  • Google Scholar

• 102

  Collins P Gutteridge C O’Driscoll A Blair S Jones L Aitchison R et al . Von Willebrand Factor as a Marker of Endothelial Cell Activation Following BMT. Bone Marrow Transplant (1992) 10(6):499–506.

  • Google Scholar

• 103

  Vannucchi A Rafanelli D Longo G Bosi A Guidi S Saccardi R et al . Early Hemostatic Alterations Following Bone Marrow Transplantation: A Prospective Study. Haematologica (1994) 79:519–25.

  • Google Scholar

• 104

  Mir E Palomo M Rovira M Pereira A Escolar G Penack O et al . Endothelial Damage is Aggravated in Acute GvHD and Could Predict its Development. Bone Marrow Transplant (2017) 52(9):1317–25. doi: 10.1038/bmt.2017.121

  • CrossRef
  • Google Scholar

• 105

  Buser TA Martinez M Drexler B Tschan-Plessl A Heim D Passweg J et al . Biological Markers of Hemostasis and Endothelial Activation in Patients With a Hematological Malignancy With or Without Stem Cell Transplants. Eur J Haematol (2019) 103(5):472–7. doi: 10.1111/ejh.13310

  • CrossRef
  • Google Scholar

• 106

  Salat C Holler E Kolb H-J Pihusch R Reinhardt B Hiller E . Endothelial Cell Markers in Bone Marrow Transplant Recipients With and Without Acute Graft-Versus-Host Disease. Bone Marrow Transplant (1997) 19(9):909–14. doi: 10.1038/sj.bmt.1700767

  • CrossRef
  • Google Scholar

• 107

  Przybyla B Pinomäki A Petäjä J Joutsi-Korhonen L Strandberg K Hillarp A et al . Coordinated Responses of Natural Anticoagulants to Allogeneic Stem Cell Transplantation and Acute GVHD - A Longitudinal Study. PLoS One (2017) 12(12):e0190007. doi: 10.1371/journal.pone.0190007

  • CrossRef
  • Google Scholar

• 108

  Biedermann BC Sahner S Gregor M Tsakiris DA Jeanneret C Pober JS et al . Endothelial Injury Mediated by Cytotoxic T Lymphocytes and Loss of Microvessels in Chronic Graft Versus Host Disease. Lancet (2002) 359(9323):2078–83. doi: 10.1016/S0140-6736(02)08907-9

  • CrossRef
  • Google Scholar

• 109

  Biedermann BC Tsakiris DA Gregor M Pober JS Gratwohl A . Combining Altered Levels of Effector Transcripts in Circulating T Cells With a Marker of Endothelial Injury is Specific for Active Graft-Versus-Host Disease. Bone Marrow Transplant (2003) 32(11):1077–84. doi: 10.1038/sj.bmt.1704258

  • CrossRef
  • Google Scholar

• 110

  Pulanic D Samardzic A Desnica L Zadro R Milosevic M Serventi Seiwerth R et al . High Levels of FVIII and Von Willebrand Factor in Chronic Graft-versus-Host Disease. The 45th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Poster Session. Bone Marrow Transplant (2019) 54:303. doi: 10.1038/s41409-019-0559-4

  • CrossRef
  • Google Scholar

• 111

  Kekre N Kim HT Ho VT Cutler C Armand P Nikiforow S et al . Venous Thromboembolism is Associated With Graft-Versus-Host Disease and Increased non-Relapse Mortality After Allogeneic Hematopoietic Stem Cell Transplantation. Haematologica (2017) 102(7):1185–91. doi: 10.3324/haematol.2017.164012

  • CrossRef
  • Google Scholar

• 112

  Xu Z Luo C Lai P Ling W Wu S Huang X et al . Von Willebrand Factor as a Predictor for Transplant-Associated Thrombotic Microangiopathy. Clin Appl Thromb (2020) 26:1–7. doi: 10.1177/1076029619892684

  • CrossRef
  • Google Scholar

• 113

  Ito-Habe N Wada H Matsumoto T Ohishi K Toyoda H Ishikawa E et al . Elevated Von Willebrand Factor Propeptide for the Diagnosis of Thrombotic Microangiopathy and for Predicting a Poor Outcome. Int J Hematol (2011) 93(1):47–52. doi: 10.1007/s12185-010-0732-4

  • CrossRef
  • Google Scholar

• 114

  Shulman HM Gown AM Nugent DJ . Hepatic Veno-Occlusive Disease After Bone Marrow Transplantation. Immunohistochemical Identification of the Material Within Occluded Central Venules. Am J Pathol (1987) 127(3):549–58.

  • Google Scholar

• 115

  Mohty M Malard F Abecassis M Aerts E Alaskar AS Aljurf M et al . Revised Diagnosis and Severity Criteria for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease in Adult Patients: A New Classification From the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant (2016) 51(7):906–12. doi: 10.1038/bmt.2016.130

  • CrossRef
  • Google Scholar

• 116

  Gabay C Kushner I . Acute-Phase Proteins and Other Systemic Responses to Inflammation. N Engl J Med (1999) 340:448–54. doi: 10.1056/NEJM199902113400607

  • CrossRef
  • Google Scholar

• 117

  Pulanic D Lozier JN Pavletic SZ . Thrombocytopenia and Hemostatic Disorders in Chronic Graft Versus Host Disease. Bone Marrow Transplant (2009) 44(7):393–403. doi: 10.1038/bmt.2009.196

  • CrossRef
  • Google Scholar

• 118

  Rayes J Bourne JH Brill A Watson SP . The Dual Role of Platelet-Innate Immune Cell Interactions in Thrombo-Inflammation. Res Pract Thromb Haemost (2020) 4(1):23–35. doi: 10.1002/rth2.12266

  • CrossRef
  • Google Scholar

• 119

  Matsuda Y Hara J Osugi Y Tokimasa S Fujisaki H Takai K et al . Serum Levels of Soluble Adhesion Molecules in Stem Cell Transplantation-Related Complications. Bone Marrow Transplant (2001) 27(9):977–82. doi: 10.1038/sj.bmt.1703026

  • CrossRef
  • Google Scholar

• 120

  Kariminia A Holtan SG Ivison S Rozmus J Hebert M-J Martin PJ et al . Heterogeneity of Chronic Graft-Versus-Host Disease Biomarkers: Association With CXCL10 and CXCR3+ NK Cells. Blood (2016) 127(24):3082–91. doi: 10.1182/blood-2015-09-668251

  • CrossRef
  • Google Scholar

• 121

  Pidala J Sarwal M Roedder S Lee SJ . Biologic Markers of Chronic GVHD. Bone Marrow Transplant (2014) 49:324–31. doi: 10.1038/bmt.2013.97

  • CrossRef
  • Google Scholar

• 122

  Yu J Storer BE Kushekhar K Zaid MA Zhang Q Gafken PR et al . Biomarker Panel for Chronic Graft-Versus-Host Disease. J Clin Oncol (2016) 34(22):2583–90. doi: 10.1200/JCO.2015.65.9615

  • CrossRef
  • Google Scholar

• 123

  Martires KJ Baird K Steinberg SM Grkovic L Joe GO Williams KM et al . Sclerotic-Type Chronic GVHD of the Skin: Clinical Risk Factors, Laboratory Markers, and Burden of Disease. Blood (2011) 118(15):4250–7. doi: 10.1182/blood-2011-04-350249

  • CrossRef
  • Google Scholar

• 124

  Bat T Steinberg SM Childs R Calvo KR Barrett AJ Battiwalla M et al . Active Thrombopoiesis is Associated With Worse Severity and Activity of Chronic GVHD. Bone Marrow Transplant (2013) 48(12):1569–73. doi: 10.1038/bmt.2013.95

  • CrossRef
  • Google Scholar

• 125

  Pihusch R Wegner H Salat C Pihusch M Holler E Kolb HJ et al . Flow Cytometric Findings in Platelets of Patients Following Allogeneic Hematopoietic Stem Cell Transplantation. Bone Marrow Transplant (2002) 30(6):381–7. doi: 10.1038/sj.bmt.1703663

  • CrossRef
  • Google Scholar

• 126

  Bozdag SC Gunaltay S Dalva K Ozcan M . Follow-Up of ADAMTS13 Enzyme and its Relationship With Clinical Events After Allogeneic Hematopoietic Stem Cell Transplantation. Blood Coagul Fibrinolysis (2009) 20(3):165–9. doi: 10.1097/MBC.0b013e3283177b30

  • CrossRef
  • Google Scholar

• 127

  McGuirk J Hao G Hou W Abhyankar S Williams C Yan W et al . Serum Proteomic Profiling and Haptoglobin Polymorphisms in Patients With GVHD After Allogeneic Hematopoietic Cell Transplantation. J Hematol Oncol (2009) 2(1):17. doi: 10.1186/1756-8722-2-17

  • CrossRef
  • Google Scholar

• 128

  Ren H-G Adom D Paczesny S . The Search for Drug-Targetable Diagnostic, Prognostic and Predictive Biomarkers in Chronic Graft-Versus-Host Disease. Expert Rev Clin Immunol (2018) 14(5):389–404. doi: 10.1080/1744666X.2018.1463159

  • CrossRef
  • Google Scholar

• 129

  Kitko CL Levine JE Storer BE Chai X Fox DA Braun TM et al . Plasma CXCL9 Elevations Correlate With Chronic GVHD Diagnosis. Blood (2014) 123(5):786–93. doi: 10.1182/blood-2013-08-520072

  • CrossRef
  • Google Scholar

• 130

  Saliba RM Sarantopoulos S Kitko CL Pawarode A Goldstein SC Magenau J et al . B-Cell Activating Factor (BAFF) Plasma Level At the Time of Chronic GvHD Diagnosis is a Potential Predictor of non-Relapse Mortality. Bone Marrow Transplant (2017) 52(7):1010–5. doi: 10.1038/bmt.2017.73

  • CrossRef
  • Google Scholar

• 131

  Liu X Yue Z Yu J Daguindau E Kushekhar K Zhang Q et al . Proteomic Characterization Reveals That MMP-3 Correlates With Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell and Lung Transplantation. Am J Transplant (2016) 16(8):2342–51. doi: 10.1111/ajt.13750

  • CrossRef
  • Google Scholar

• 132

  Großekatthöfer M Güclü ED Lawitschka A Matthes-Martin S Mann G Minkov M et al . Ferritin Concentrations Correlate to Outcome of Hematopoietic Stem Cell Transplantation But do Not Serve as Biomarker of Graft-Versus-Host Disease. Ann Hematol (2013) 92(8):1121–8. doi: 10.1007/s00277-013-1737-x

  • CrossRef
  • Google Scholar

• 133

  Shimura K Ashihara E Shimazaki C Matsunaga S Taniguchi K Uchiyama H et al . Circulating Endothelial Progenitor Cells Decreased in Patients With Sclerodermatous Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant (2008) 14(4):426–37. doi: 10.1016/j.bbmt.2008.02.001

  • CrossRef
  • Google Scholar

• 134

  Hildebrandt GC Chao N . Endothelial Cell Function and Endothelial-Related Disorders Following Haematopoietic Cell Transplantation. Br J Haematol (2020) 190:508–19. doi: 10.1111/bjh.16621

  • CrossRef
  • Google Scholar

• 135

  Tichelli A Gratwohl A . Vascular Endothelium as ‘Novel’ Target of Graft-Versus-Host Disease. Best Pract Res Clin Haematol (2008) 21(2):139–48. doi: 10.1016/j.beha.2008.02.002

  • CrossRef
  • Google Scholar

• 136

  Biedermann BC Pober JS . Human Vascular Endothelial Cells Favor Clonal Expansion of Unusual Alloreactive CTL. J Immunol (1999) 162:7022–30.

  • Google Scholar

• 137

  Eissner G Hartmann I Kesikli A Holler E Haffner S Sax T et al . CD4+CD25+FoxP3+ Regulatory T-Cells Enhance the Allogeneic Activity of Endothelial-Specific CD8+/CD28- Cytotoxic T Lymphocytes. Int Immunol (2011) 23:485–92. doi: 10.1093/intimm/dxr041

  • CrossRef
  • Google Scholar

• 138

  Luft T Dietrich S Falk C Conzelmann M Hess M Benner A et al . Steroid-Refractory GVHD: T-Cell Attack Within a Vulnerable Endothelial System. Blood (2011) 118(6):1685–92. doi: 10.1182/blood-2011-02-334821

  • CrossRef
  • Google Scholar

• 139

  Cordes S Mokhtari Z Bartosova M Mertlitz S Riesner K Shi Y et al . Endothelial Damage and Dysfunction in Acute Graft-Versus-Host Disease. Haematologica (2020) 105. doi: 10.3324/haematol.2020.253716

  • CrossRef
  • Google Scholar

• 140

  Martinez-Sanchez J Hamelmann H Palomo M Mir E Moreno-Castaño AB Torramade S et al . Acute Graft-vs.-Host Disease-Associated Endothelial Activation In Vitro Is Prevented by Defibrotide. Front Immunol (2019) 10:2339. doi: 10.3389/fimmu.2019.02339

  • CrossRef
  • Google Scholar

• 141

  García-Bernal D Palomo M Martínez CM Millán-Rivero JE García-Guillén AI Blanquer M et al . Defibrotide Inhibits Donor Leucocyte-Endothelial Interactions and Protects Against Acute Graft-Versus-Host Disease. J Cell Mol Med (2020) 24(14):8031–44. doi: 10.1111/jcmm.15434

  • CrossRef
  • Google Scholar

• 142

  Eissner G Multhoff G Gerbitz A Kirchner S Haffner S Sondermann D et al . Fludarabine Induces Apoptosis, Activation and Allogenicity in Human Endothelial and Epithelial Cells, Protective Role of Defibrotide. Blood (2002) 100:334–40. doi: 10.1182/blood.V100.1.334

  • CrossRef
  • Google Scholar

• 143

  Kreisel D Krupnick AS Gelman AE Engels FH Popma SH Krasinskas AM et al . Non-Hematopoietic Allograft Cells Directly Activate CD8+ T Cells and Trigger Acute Rejection: An Alternative Mechanism of Allorecognition. Nat Med (2002) 8:233–9. doi: 10.1038/nm0302-233

  • CrossRef
  • Google Scholar

• 144

  Penack O Socié G Van Den Brink MRM . The Importance of Neovascularization and its Inhibition for Allogeneic Hematopoietic Stem Cell Transplantation. Blood (2011) 117:4181–9. doi: 10.1182/blood-2010-10-312934

  • CrossRef
  • Google Scholar

• 145

  Haeusermann P Kump E Rovo A Tichelli A Itin P Gratwohl A et al . Partial Reconstitution of Cutaneous Microvessels in Long-Term Survivors After Allogeneic Bone Marrow Transplantation. Dermatology (2009) 219(1):32–41. doi: 10.1159/000216934

  • CrossRef
  • Google Scholar

• 146

  Willemze AJ Bakker AC Von Dem Borne PA Bajema IM Vossen JM . The Effect of Graft-Versus-Host Disease on Skin Endothelial and Epithelial Cell Chimerism in Stem-Cell Transplant Recipients. Transplantation (2009) 87(7):1096–101. doi: 10.1097/TP.0b013e31819d340f

  • CrossRef
  • Google Scholar

• 147

  Gavriilaki E Sakellari I Anyfanti P Batsis I Vardi A Bousiou Z et al . Assessment of Endothelial Injury and Pro-Coagulant Activity Using Circulating Microvesicles in Survivors of Allogeneic Hematopoietic Cell Transplantation. Int J Mol Sci (2020) 21(24):9768. doi: 10.3390/ijms21249768

  • CrossRef
  • Google Scholar